---
title: "Odyssey posts June 2026 corporate presentation highlighting OD-001 Phase 2a results and $464M pro forma cash"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290566512.md"
description: "Odyssey Therapeutics released a June 2026 corporate presentation highlighting positive Phase 2a results for OD-001 in ulcerative colitis, meeting primary endpoints with significant clinical remission and safety. The company reported a pro forma cash position of $464 million as of March 31, 2026, supporting operations through late 2028. Pipeline updates include expected Phase 2b readouts in 2H 2027 and broader franchise data by 2028."
datetime: "2026-06-23T12:53:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290566512.md)
  - [en](https://longbridge.com/en/news/290566512.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290566512.md)
---

# Odyssey posts June 2026 corporate presentation highlighting OD-001 Phase 2a results and $464M pro forma cash

**Odyssey posted a June 2026 corporate presentation highlighting positive Phase 2a OD-001 data, development timelines, and a $464M pro forma cash position.**

**Key Highlights:**

-   Furnished corporate presentation (Exhibit 99.1) disclosing OD-001 Phase 2a topline: primary endpoint met (MMCS change -2.6, p < 0.001) across 49 patients.
-   OD-001 showed clinical remission, endoscopic improvement and promising efficacy in both advanced-therapy naïve and experienced UC patients.
-   Safety: OD-001 well tolerated at 10 mg and 20 mg BID; no drug-related SAEs or grade ≥3 TEAEs reported in presented data.
-   Pipeline and milestones: OD-001 combo and Phase 2b monotherapy readouts expected 2H 2027; maintenance and broader franchise data expected by 2028.
-   Balance sheet: $464 million cash pro forma as of March 31, 2026, supporting runway into 2H 2028 and ongoing IND-enabling programs (OD-002, OD-003).

Original SEC Filing: Odyssey Therapeutics, Inc. \[ ODTX \] - 8-K - Jun. 23, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ODTX.US](https://longbridge.com/en/quote/ODTX.US.md)

## Related News & Research

- [Bio-Techne declares Q3 2026 distribution of R$ 0.01 per unit, payable Sept. 10](https://longbridge.com/en/news/296357843.md)
- [Cemig authorizes release of Q2 2026 interim financial statements (ITR)](https://longbridge.com/en/news/296491066.md)
- [Bio-Techne declares Q3 2026 distribution of R$ 0.01 per unit, payable Sept. 3](https://longbridge.com/en/news/295953690.md)
- [Assurant declares Q3 2026 distribution of R$ 0.77 per unit, payable Oct. 2](https://longbridge.com/en/news/296117099.md)
- [Rockwool announces availability of 2026 half-year report](https://longbridge.com/en/news/296326112.md)